Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B231c03a3d8965baf298c57caf6b7058a> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B231c03a3d8965baf298c57caf6b7058a NCIT_P378 "NCI" @default.
- B231c03a3d8965baf298c57caf6b7058a type Axiom @default.
- B231c03a3d8965baf298c57caf6b7058a annotatedProperty IAO_0000115 @default.
- B231c03a3d8965baf298c57caf6b7058a annotatedSource NCIT_C104048 @default.
- B231c03a3d8965baf298c57caf6b7058a annotatedTarget "A proprietary oral formulation composed of the poorly soluble, synthetic triazole agent, itraconazole, dispersed in a polymer matrix, with antifungal and potential anti-angiogenic activities. Upon oral administration, itraconazole inhibits the enzyme cytochrome P450 lanosterol 14 alpha-demethylase, resulting in a decrease in fungal ergosterol synthesis. Although the exact mechanism through which itraconazole inhibits angiogenesis has yet to be fully elucidated, this agent appears to inhibit the Hedgehog (Hh) signaling pathway, cholesterol synthesis and mammalian target of rapamycin (mTOR) signaling in endothelial cells. This agent may also prevent the activation of and signaling by various angiogenic growth factors. By decreasing the tumor vasculature and nutrient supply, itraconazole ultimately inhibits tumor cell growth. The solid dispersion of itraconazole in the polymer matrix enhances dissolution of itraconazole in the gastrointestinal tract and increases its bioavailability; this allows for the administration of a much lower dose compared to itraconazole alone." @default.